Anastasia D. Rodina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anastasia D. Rodina has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Vladimir G. Polyakov
N.N. Blokhin National Medical Research Center of Oncology of Ministry of Health of the Russian Federation
13 shared publications - Tatiana V. Gorbunova
N.N. Blokhin National Medical Research Center of Oncology of Ministry of Health of the Russian Federation
10 shared publications - Alexander S. Krylov
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
7 shared publications - Svetlana R. Varfolomeeva
N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia
6 shared publications - Natalia V. Ivanova
N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia
5 shared publications - Akgul A. Odzharova
N.N. Blokhin National Medical Research Center of Oncology
4 shared publications
Latest Publications
- Open Access
- 12 August 2026
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 13 (2) , 128-138
The phenomenon of diffuse infiltrative retinoblastoma with metastatic lesions of the brain and spinal cord. Own clinical observation with a review of the literature
Diffuse infiltrative retinoblastoma (RB) is a rare form of RB, which is the most malignant, first described by N. Ashton in 1958. Its occurrence among all forms of RB according to previously published articles ranges from 2.0 to 4.6 %. The article presents a unique case of diffuse infiltrative RB with extensive damage to the central nervous system, which resulted in remission in a child with a primary diagnosis of the disease at the age of 11 years.
- 12 August 2026
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 13 (2) , 128-138
Open AccessThe phenomenon of diffuse infiltrative retinoblastoma with metastatic lesions of the brain and spinal cord. Own clinical observation with a review of the literature
Diffuse infiltrative retinoblastoma (RB) is a rare form of RB, which is the most malignant, first described by N. Ashton in 1958. Its occurrence among all forms of RB according to previously published articles ranges from 2.0 to 4.6 %. The article presents a unique case of diffuse infiltrative RB with extensive damage to the central nervous system, which resulted in remission in a child with a primary diagnosis of the disease at the age of 11 years.
- 7 April 2026
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 25 (1)
Intrathecal chemotherapy in the complex treatment of children with parameningeal rhabdomyosarcoma with intracranial spread and/ or leptomeningeal metastasis
Introduction . Parameningeal rhabdomyosarcoma with intracranial spread is a highly aggressive pediatric malignancy with a high risk of leptomeningeal metastasis. Historically, central nervous system (CNS) involvement was considered an incurable condition with a survival rate of no more than 10–20 %. The bloodbrain barrier is the primary barrier to the penetration of most drugs and the creation of effective concentrations. Therefore, the search for effective and non-toxic methods for controlling leptomeningeal metastases is one of the most pressing challenges in pediatric oncology. Intrathecal chemotherapy (ITCT) delivers cancer drugs directly into the cerebrospinal fuid, bypassing the BBB. It enables high concentrations of medication to directly target cells, reducing systemic toxicity. The purpose of the study was to evaluate the effcacy and safety of intrathecal chemotherapy in a multidisciplinary approach to the treatment of children with parameningeal rhabdomyosarcoma with intracranial spread and/or leptomeningeal metastasis, and to improve survival rates in this cohort of children. Material and Methods . The study included 21 patients with a histologically verifed diagnosis of parameningeal rhabdomyosarcoma with intracranial spread and/or leptomeningeal metastasis, who received treatment at the L.A. Durnov Research Institute of Pediatric Oncology and Hematology of the Russian Academy of Medical Sciences from 2021 to 2024. The study was approved by the local ethics committee. Results . With a 34.3-month median follow-up, the overall 2-year survival rate was 65 %. This indicates the effectiveness of early tumor control by overcoming the blood-brain barrier. The overall 2-year survival rate was signifcantly higher in both the prophylactic and therapeutic frst-line intrathecal chemotherapy groups than in the relapse group (80 % vs 20 %, pConclusion . Intensive intrathecal chemotherapy in the combination treatment of children with parameningeal rhabdomyosarcoma with intracranial extension and/or leptomeningeal metastasis is an effective and safe method for treating and preventing CNS tumor cell infltration. This therapy can signifcantly improve survival of patients with extremely unfavorable prognosis.
- 7 April 2026
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 25 (1)
Intrathecal chemotherapy in the complex treatment of children with parameningeal rhabdomyosarcoma with intracranial spread and/ or leptomeningeal metastasis
Introduction . Parameningeal rhabdomyosarcoma with intracranial spread is a highly aggressive pediatric malignancy with a high risk of leptomeningeal metastasis. Historically, central nervous system (CNS) involvement was considered an incurable condition with a survival rate of no more than 10–20 %. The bloodbrain barrier is the primary barrier to the penetration of most drugs and the creation of effective concentrations. Therefore, the search for effective and non-toxic methods for controlling leptomeningeal metastases is one of the most pressing challenges in pediatric oncology. Intrathecal chemotherapy (ITCT) delivers cancer drugs directly into the cerebrospinal fuid, bypassing the BBB. It enables high concentrations of medication to directly target cells, reducing systemic toxicity. The purpose of the study was to evaluate the effcacy and safety of intrathecal chemotherapy in a multidisciplinary approach to the treatment of children with parameningeal rhabdomyosarcoma with intracranial spread and/or leptomeningeal metastasis, and to improve survival rates in this cohort of children. Material and Methods . The study included 21 patients with a histologically verifed diagnosis of parameningeal rhabdomyosarcoma with intracranial spread and/or leptomeningeal metastasis, who received treatment at the L.A. Durnov Research Institute of Pediatric Oncology and Hematology of the Russian Academy of Medical Sciences from 2021 to 2024. The study was approved by the local ethics committee. Results . With a 34.3-month median follow-up, the overall 2-year survival rate was 65 %. This indicates the effectiveness of early tumor control by overcoming the blood-brain barrier. The overall 2-year survival rate was signifcantly higher in both the prophylactic and therapeutic frst-line intrathecal chemotherapy groups than in the relapse group (80 % vs 20 %, pConclusion . Intensive intrathecal chemotherapy in the combination treatment of children with parameningeal rhabdomyosarcoma with intracranial extension and/or leptomeningeal metastasis is an effective and safe method for treating and preventing CNS tumor cell infltration. This therapy can signifcantly improve survival of patients with extremely unfavorable prognosis.
- 3 April 2026
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 13 (1)
Transnasal endoscopic surgery in the complex treatment of children with parameningeal rhabdomyosarcoma
Introduction. Malignant tumors of the parameningeal region are neoplasms with varying morphologies. The most common malignant tumors of this location are rhabdomyosarcoma, esthesioneuroblastoma, and undifferentiated carcinoma. Rhabdomyosarcoma is the most common soft tissue sarcoma. The incidence rate of rhabdomyosarcoma is 0.9 per 100,000 children. According to the Children's Oncology Group, comprehensive, intensive antitumor treatment, including multiagent chemotherapy, radiation therapy, and modern surgical technologies, has increased overall 5-year survival rates to 70 %. Developing in these anatomical structures, rhabdomyosarcoma involves several adjacent anatomical areas, including the visual system and the brain. Treatment of children with parameningeal rhabdomyosarcoma requires not only achieving oncological radicality but also minimizing the long-term consequences of therapy that impact quality of life. In this context, the choice of surgical approach – between traditional open surgeries and transnasal endoscopic surgery – takes on particular importance. Open approaches, despite their effectiveness, carry the risk of damaging the facial growth plates and causing significant cosmetic defects. However, transnasal endoscopic surgery avoids these drawbacks while ensuring adequate oncologic control, making it an increasingly preferred method in pediatric practice. The aim of the study – demonstratation of the capabilities and advantages of transnasal endoscopic surgery in the treatment of children with parameningeal rhabdomyosarcoma. Materials and methods . The study included 36 patients aged 9 months to 14 years diagnosed with parameningeal rhabdomyosarcoma who underwent specialized treatment between 2017 and 2022. Boys predominated – 20 (56 %). All patients underwent surgical treatment at the Research Institute of Preschool Education and Gynecology, N.N. Blokhin National Medical Research Center, Ministry of Health, Russia. Results. After a median follow-up of 60 months, 25 patients (68 %) in the study group are alive. Deaths occurred in 10 patients (29 %), of which 9 (26 %) were due to disease progression, and 1 (3 %) was due to complications of the treatment. One patient (3 %) was lost to follow-up. Conclusions. The expanded use of transnasal endoscopic surgery in the treatment of children with parameningeal rhabdomyosarcoma is driven by a unique combination of advantages: excellent intraoperative visualization, ensuring radical intervention, and minimal trauma, preserving intact anatomical structures. Further development of this technique, in turn, is stimulated by technological innovations and close interdisciplinary collaboration.
- 3 April 2026
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 13 (1)
Transnasal endoscopic surgery in the complex treatment of children with parameningeal rhabdomyosarcoma
Introduction. Malignant tumors of the parameningeal region are neoplasms with varying morphologies. The most common malignant tumors of this location are rhabdomyosarcoma, esthesioneuroblastoma, and undifferentiated carcinoma. Rhabdomyosarcoma is the most common soft tissue sarcoma. The incidence rate of rhabdomyosarcoma is 0.9 per 100,000 children. According to the Children's Oncology Group, comprehensive, intensive antitumor treatment, including multiagent chemotherapy, radiation therapy, and modern surgical technologies, has increased overall 5-year survival rates to 70 %. Developing in these anatomical structures, rhabdomyosarcoma involves several adjacent anatomical areas, including the visual system and the brain. Treatment of children with parameningeal rhabdomyosarcoma requires not only achieving oncological radicality but also minimizing the long-term consequences of therapy that impact quality of life. In this context, the choice of surgical approach – between traditional open surgeries and transnasal endoscopic surgery – takes on particular importance. Open approaches, despite their effectiveness, carry the risk of damaging the facial growth plates and causing significant cosmetic defects. However, transnasal endoscopic surgery avoids these drawbacks while ensuring adequate oncologic control, making it an increasingly preferred method in pediatric practice. The aim of the study – demonstratation of the capabilities and advantages of transnasal endoscopic surgery in the treatment of children with parameningeal rhabdomyosarcoma. Materials and methods . The study included 36 patients aged 9 months to 14 years diagnosed with parameningeal rhabdomyosarcoma who underwent specialized treatment between 2017 and 2022. Boys predominated – 20 (56 %). All patients underwent surgical treatment at the Research Institute of Preschool Education and Gynecology, N.N. Blokhin National Medical Research Center, Ministry of Health, Russia. Results. After a median follow-up of 60 months, 25 patients (68 %) in the study group are alive. Deaths occurred in 10 patients (29 %), of which 9 (26 %) were due to disease progression, and 1 (3 %) was due to complications of the treatment. One patient (3 %) was lost to follow-up. Conclusions. The expanded use of transnasal endoscopic surgery in the treatment of children with parameningeal rhabdomyosarcoma is driven by a unique combination of advantages: excellent intraoperative visualization, ensuring radical intervention, and minimal trauma, preserving intact anatomical structures. Further development of this technique, in turn, is stimulated by technological innovations and close interdisciplinary collaboration.
- Open Access
- 12 August 2024
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 11 (2) , 97-107
Unclassified carcinoma of the scalp in a child. Clinical case with literature review
Malignant tumors of the scalp are neoplasms of various morphologies. The most common malignant tumors of this localization are basal cell and squamous cell skin cancer, accounting for 95 % of all neoplasms in adults. Malignant tumors of the scalp in children account for no more than 0.2 % of all malignant tumors in childhood, of which unclassified carcinoma accounts for 0.1 %. The etiological factors of unclassified skin carcinoma are unknown, but previous factors include genetic predisposition, hemorrhage after trauma. The specific anatomical structure of the scalp (high density of hair follicles, the presence of hair), as well as the lack of specificity of symptoms and signs, leads to late diagnosis of skin tumors, which affects treatment and prognosis. CT-scan better diagnoses the condition of bone structures, and magnetic resonance imaging better assesses the presence of intracranial spread and the degree of involvement of brain structures. The difficulty of differential diagnosis of rare morphological variants of skin tumors in children lies in the lack of a unified database of rare skin tumors of childhood. To treat patients with malignant tumors of the scalp, combined antitumor treatment is used, including multicomponent chemotherapy, radiation therapy, and modern surgical technologies. Currently, unclassified skin carcinoma remains poorly understood. Therefore, the treatment of this cohort of patients requires a multidisciplinary approach.
- 12 August 2024
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 11 (2) , 97-107
Open AccessUnclassified carcinoma of the scalp in a child. Clinical case with literature review
Malignant tumors of the scalp are neoplasms of various morphologies. The most common malignant tumors of this localization are basal cell and squamous cell skin cancer, accounting for 95 % of all neoplasms in adults. Malignant tumors of the scalp in children account for no more than 0.2 % of all malignant tumors in childhood, of which unclassified carcinoma accounts for 0.1 %. The etiological factors of unclassified skin carcinoma are unknown, but previous factors include genetic predisposition, hemorrhage after trauma. The specific anatomical structure of the scalp (high density of hair follicles, the presence of hair), as well as the lack of specificity of symptoms and signs, leads to late diagnosis of skin tumors, which affects treatment and prognosis. CT-scan better diagnoses the condition of bone structures, and magnetic resonance imaging better assesses the presence of intracranial spread and the degree of involvement of brain structures. The difficulty of differential diagnosis of rare morphological variants of skin tumors in children lies in the lack of a unified database of rare skin tumors of childhood. To treat patients with malignant tumors of the scalp, combined antitumor treatment is used, including multicomponent chemotherapy, radiation therapy, and modern surgical technologies. Currently, unclassified skin carcinoma remains poorly understood. Therefore, the treatment of this cohort of patients requires a multidisciplinary approach.
- Open Access
- 21 July 2024
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 23 (2) , 116-127
Complications of high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation in children with solid malignant neoplasms: a single-center experience
High-dose chemotherapy (HDCT) followed by autologous hematopoietic stem cell transplantation (auto-HSCT) is a therapeutic option that allows potentiating the antitumor effect in patients with malignant neoplasms (MNs) belonging to the high-risk group. However, despite the effectiveness of this method, the risks of developing infectious and toxic complications in the early and late post-transplantation period are higher than the risks associated with treatment according to standard protocols and can significantly worsen the results of transplantation. We carried out a retrospective analysis of the results of auto-HSCT in a cohort of 156 patients with high-risk solid MNs treated at the L.A. Durnov Research Institute of Pediatric Oncology and Hematology, the N.N. Blokhin National Medical Research Center of Oncology of Ministry of Healthcare of the Russian Federation in 2020–2023. The study was approved by the Independent Ethics Committee and the Scientific Council of the N.N. Blokhin National Medical Research Center of Oncology. The study included 78 (50%) boys and 78 (50%) girls, the median age of the patients was 8 years 7 months (9 months – 17 years 8 months). Auto-HSCT was performed in 90 (57.7%) patients with neuroblastoma, 25 (16.0%) – with Ewing's sarcoma, 16 (10.3%) – with germ cell tumors, 13 (8.4%) – with nephroblastoma, 7 (4.5%) – with retinoblastoma, 3 (1.9%) – with medulloblastoma, 1 (0.6%) patient with pleuropulmonary blastoma and 1 (0.6%) patient with sialoblastoma. We used the following conditioning regimens: treosulfan + melphalan (n = 116), carboplatin + thiotepa + etoposide (n = 17), melphalan (n = 13), carboplatin + thiotepa + etoposide + cyclophosphamide (n = 10). Depending on the clinical indications and the treatment protocol used, 136 (87.2%) patients underwent one course of HDCT, and 20 (12.8%) patients underwent tandem HDCT. In most patients, the median recovery time for granulocytes and platelets was 11 (8–19) days and 14 (12–21) days, respectively. The most common infectious complications in patients after auto-HSCT were mucositis (89.1%), neutropenic enterocolitis (76.9%), febrile neutropenia (71.2%), less often: catheter-associated bloodstream infection (9%), pneumonia (14.1%), acute respiratory distress syndrome (0.6%). As regards toxic complications, all patients had emetic syndrome, 98 (62.8%) had dermatological toxicity, 9 (5.8%) had hemorrhagic cystitis, 116 (74.3%) had hepatic toxicity, 14 (9%) had neurotoxicity, 102 (65.4%) had moderate nutritional insufficiency. Episodes of hemorrhagic syndrome due to thrombocytopenia were observed in 44.2% of patients. After auto-HSCT, most patients develop chemotherapy-induced (including infectious) complications, which can not only significantly disrupt the patients’ well-being and quality of life, but also, depending on the severity, pose a threat to their life. The correct choice of conditioning regimen, effective collection of hematopoietic stem cells, complex accompanying therapy, timely diagnosis and treatment of complications can significantly improve the results of auto-HSCT in children with high-risk solid MNs.
- 21 July 2024
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 23 (2) , 116-127
Open AccessComplications of high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation in children with solid malignant neoplasms: a single-center experience
High-dose chemotherapy (HDCT) followed by autologous hematopoietic stem cell transplantation (auto-HSCT) is a therapeutic option that allows potentiating the antitumor effect in patients with malignant neoplasms (MNs) belonging to the high-risk group. However, despite the effectiveness of this method, the risks of developing infectious and toxic complications in the early and late post-transplantation period are higher than the risks associated with treatment according to standard protocols and can significantly worsen the results of transplantation. We carried out a retrospective analysis of the results of auto-HSCT in a cohort of 156 patients with high-risk solid MNs treated at the L.A. Durnov Research Institute of Pediatric Oncology and Hematology, the N.N. Blokhin National Medical Research Center of Oncology of Ministry of Healthcare of the Russian Federation in 2020–2023. The study was approved by the Independent Ethics Committee and the Scientific Council of the N.N. Blokhin National Medical Research Center of Oncology. The study included 78 (50%) boys and 78 (50%) girls, the median age of the patients was 8 years 7 months (9 months – 17 years 8 months). Auto-HSCT was performed in 90 (57.7%) patients with neuroblastoma, 25 (16.0%) – with Ewing's sarcoma, 16 (10.3%) – with germ cell tumors, 13 (8.4%) – with nephroblastoma, 7 (4.5%) – with retinoblastoma, 3 (1.9%) – with medulloblastoma, 1 (0.6%) patient with pleuropulmonary blastoma and 1 (0.6%) patient with sialoblastoma. We used the following conditioning regimens: treosulfan + melphalan (n = 116), carboplatin + thiotepa + etoposide (n = 17), melphalan (n = 13), carboplatin + thiotepa + etoposide + cyclophosphamide (n = 10). Depending on the clinical indications and the treatment protocol used, 136 (87.2%) patients underwent one course of HDCT, and 20 (12.8%) patients underwent tandem HDCT. In most patients, the median recovery time for granulocytes and platelets was 11 (8–19) days and 14 (12–21) days, respectively. The most common infectious complications in patients after auto-HSCT were mucositis (89.1%), neutropenic enterocolitis (76.9%), febrile neutropenia (71.2%), less often: catheter-associated bloodstream infection (9%), pneumonia (14.1%), acute respiratory distress syndrome (0.6%). As regards toxic complications, all patients had emetic syndrome, 98 (62.8%) had dermatological toxicity, 9 (5.8%) had hemorrhagic cystitis, 116 (74.3%) had hepatic toxicity, 14 (9%) had neurotoxicity, 102 (65.4%) had moderate nutritional insufficiency. Episodes of hemorrhagic syndrome due to thrombocytopenia were observed in 44.2% of patients. After auto-HSCT, most patients develop chemotherapy-induced (including infectious) complications, which can not only significantly disrupt the patients’ well-being and quality of life, but also, depending on the severity, pose a threat to their life. The correct choice of conditioning regimen, effective collection of hematopoietic stem cells, complex accompanying therapy, timely diagnosis and treatment of complications can significantly improve the results of auto-HSCT in children with high-risk solid MNs.
- Open Access
- 30 November 2023
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 10 (3) , 89-100
CMMRD-associated embryonic rhabdomyosarcoma in a child. Clinical case with literature review
Introduction. Hereditary disorders in the DNA repair system can lead to the development of malignant neoplasms in childhood. DNA constitutional mismatch repair deficiency syndrome (CMMRD) is a very rare genetic autosomal recessive disorder caused by homozygous mutations in one of the four mismatch repair genes (MLH1, MSH2, MSH6, and PMS2). The frequency of occurrence is 0.0000001 of the adult and child population. For now about 150 observations have been published in the world literature. The prognosis for CMMRD syndrome is extremely unfavorable. The spectrum of tumors that make up the CMMRD syndrome is very wide, and includes mainly malignant brain tumors, tumors of the digestive tract, hematological malignancies, embryonic tumors, all of which develop in childhood.The purpose of the study is to report a case of CMMRD-associated embryonic rhabdomyosarcoma in a 3-year-old child.Conclusions. A review of the literature and the clinical case we have described show that rhabdomyosarcoma belongs to the tumor spectrum of the CMMRD syndrome. An immunohistochemical study revealed an isolated loss of PMS2 gene expression. Taking into account the clinical course of the CMMRD syndrome, a thorough study of the family history in patients with rhabdomyosarcoma is recommended, as well as a molecular genetic study, including the search for germinal mutations in genes in the DNA repair system and the assessment of microsatellite instability in the material of the tumor tissue. The clinical symptoms of CMMRD syndrome are nonspecific and depend on the morphological variant of the primary tumor. Distinctive molecular genetic features of this syndrome are: homozygous mutations with loss of function of the germline genes of the MMR system (mismatch repair) (MLH1, MSH2, MSH6 or PMS2).
- 30 November 2023
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 10 (3) , 89-100
Open AccessCMMRD-associated embryonic rhabdomyosarcoma in a child. Clinical case with literature review
Introduction. Hereditary disorders in the DNA repair system can lead to the development of malignant neoplasms in childhood. DNA constitutional mismatch repair deficiency syndrome (CMMRD) is a very rare genetic autosomal recessive disorder caused by homozygous mutations in one of the four mismatch repair genes (MLH1, MSH2, MSH6, and PMS2). The frequency of occurrence is 0.0000001 of the adult and child population. For now about 150 observations have been published in the world literature. The prognosis for CMMRD syndrome is extremely unfavorable. The spectrum of tumors that make up the CMMRD syndrome is very wide, and includes mainly malignant brain tumors, tumors of the digestive tract, hematological malignancies, embryonic tumors, all of which develop in childhood.The purpose of the study is to report a case of CMMRD-associated embryonic rhabdomyosarcoma in a 3-year-old child.Conclusions. A review of the literature and the clinical case we have described show that rhabdomyosarcoma belongs to the tumor spectrum of the CMMRD syndrome. An immunohistochemical study revealed an isolated loss of PMS2 gene expression. Taking into account the clinical course of the CMMRD syndrome, a thorough study of the family history in patients with rhabdomyosarcoma is recommended, as well as a molecular genetic study, including the search for germinal mutations in genes in the DNA repair system and the assessment of microsatellite instability in the material of the tumor tissue. The clinical symptoms of CMMRD syndrome are nonspecific and depend on the morphological variant of the primary tumor. Distinctive molecular genetic features of this syndrome are: homozygous mutations with loss of function of the germline genes of the MMR system (mismatch repair) (MLH1, MSH2, MSH6 or PMS2).
- Open Access
- 1 February 2023
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 9 (4) , 27-36
Risk of leptomeningeal metastasis in children with parameningeal rhabdomyosarcoma with intracranial spread
Introduction. Soft tissue tumors account for up to 8 % of all malignant neoplasms in children. According to the international histological classification, about 150 different morphological variants of soft tissue tumors have been registered, of which 45 % are rhabdomyosarcoma (RMS). Most often, RMS occurs in early childhood – the average age of patients at the time of diagnosis is 5 years. The incidence rate of RMS is 0.9 per 100,000 children. In 25 % cases, the initial diagnosis reveals distant metastasis to the lungs, bones, bone marrow, and 8 % – leptomeningeal metastasis. More than 7 % of patients with localized parameningeal RMS develop leptomeningeal metastasis, according to the Rhabdomyosarcoma Study Group. Purpose of the study – report the incidence, prognosis of leptomeningeal metastasis and treatment outcomes in children with intracranial spread of RMS. Materials and methods. The study included 45 patients aged 1 to 17 years with a diagnosis of RMS of parameningeal localization with intracranial spread, who received special treatment from 2003 to 2020. The study included 6 (20 %) patients in whom the tumor developed in early childhood (up to 3 years). The boys predominated – 25 (55.5 %) in the study. The primary tumor spread to the orbit in 7 (15 %) cases, the skull base in 7 (15 %) cases, the middle ear in 4 (8 %) cases, the nasopharynx in 3 (6 %) cases, and the brain substance was affected in 16 (35 %). Metastases in regional lymph nodes were determined in 7 (15 %) patients. Multiple metastatic lesions of bones and bone marrow – 4 (9 %) cases, leptomeningeal metastases – in 2 (4 %). 45 (100 %) patients received drug treatment according to the protocols approved by the Academic Council of the Research Institute of Pediatric Oncology and Hematology at N. N. Blokhin National Medical Research Centerof Oncology, Ministry of Health of Russia. Radiation therapy was performed in 33 (74 %) patients, while total focal dose of 50 Gy was administered to the primary tumor. Affected lymph nodes of the neck were irradiated in 10 (23 %) patients, total focal dose is 45.0 Gy. Surgical treatment was performed in 15 (34 %) patients. Multicomponent treatment was performed in 15 (34 %) patients. Results. During the observation period from 12 months to 14 years, 21 (49 %) patients are alive. 21 (51 %) patients died from tumor progression, 1 (2 %) died from complications of special treatment. Conclusions. The treatment of this group of patients is one of the urgent problems of pediatric oncology, which is based on polychemotherapy, supplemented by intrathecal administration of anticancer drugs and craniospinal irradiation. The development of new therapies requires a multidisciplinary approach to achieve a significant improvement in the survival of children with leptomeningeal metastases RMS of parameningeal localization.
- 1 February 2023
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 9 (4) , 27-36
Open AccessRisk of leptomeningeal metastasis in children with parameningeal rhabdomyosarcoma with intracranial spread
Introduction. Soft tissue tumors account for up to 8 % of all malignant neoplasms in children. According to the international histological classification, about 150 different morphological variants of soft tissue tumors have been registered, of which 45 % are rhabdomyosarcoma (RMS). Most often, RMS occurs in early childhood – the average age of patients at the time of diagnosis is 5 years. The incidence rate of RMS is 0.9 per 100,000 children. In 25 % cases, the initial diagnosis reveals distant metastasis to the lungs, bones, bone marrow, and 8 % – leptomeningeal metastasis. More than 7 % of patients with localized parameningeal RMS develop leptomeningeal metastasis, according to the Rhabdomyosarcoma Study Group. Purpose of the study – report the incidence, prognosis of leptomeningeal metastasis and treatment outcomes in children with intracranial spread of RMS. Materials and methods. The study included 45 patients aged 1 to 17 years with a diagnosis of RMS of parameningeal localization with intracranial spread, who received special treatment from 2003 to 2020. The study included 6 (20 %) patients in whom the tumor developed in early childhood (up to 3 years). The boys predominated – 25 (55.5 %) in the study. The primary tumor spread to the orbit in 7 (15 %) cases, the skull base in 7 (15 %) cases, the middle ear in 4 (8 %) cases, the nasopharynx in 3 (6 %) cases, and the brain substance was affected in 16 (35 %). Metastases in regional lymph nodes were determined in 7 (15 %) patients. Multiple metastatic lesions of bones and bone marrow – 4 (9 %) cases, leptomeningeal metastases – in 2 (4 %). 45 (100 %) patients received drug treatment according to the protocols approved by the Academic Council of the Research Institute of Pediatric Oncology and Hematology at N. N. Blokhin National Medical Research Centerof Oncology, Ministry of Health of Russia. Radiation therapy was performed in 33 (74 %) patients, while total focal dose of 50 Gy was administered to the primary tumor. Affected lymph nodes of the neck were irradiated in 10 (23 %) patients, total focal dose is 45.0 Gy. Surgical treatment was performed in 15 (34 %) patients. Multicomponent treatment was performed in 15 (34 %) patients. Results. During the observation period from 12 months to 14 years, 21 (49 %) patients are alive. 21 (51 %) patients died from tumor progression, 1 (2 %) died from complications of special treatment. Conclusions. The treatment of this group of patients is one of the urgent problems of pediatric oncology, which is based on polychemotherapy, supplemented by intrathecal administration of anticancer drugs and craniospinal irradiation. The development of new therapies requires a multidisciplinary approach to achieve a significant improvement in the survival of children with leptomeningeal metastases RMS of parameningeal localization.
- Open Access
- 10 December 2022
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 12 (4) , 91-101
Distant metastasis of alveolar rhabdomyosarcoma with pancreatic parameningeal localization in children: clinical case series
Rhabdomyosarcoma is a malignant neoplasm that develops from embryonic mesenchymal cells, with an annual incidence of 4.3 cases per 1,000,000 children. The prevalence of the tumor process is estimated on the basis of data from a comprehensive examination, including magnetic resonance imaging with intravenous contrast, ultrasound examination of the primary focus of regional and distant metastasis zones, computed tomography and radioisotope studies. The overall 5-year survival rate for localized rhabdomyosarcoma reaches 70 %. During the initial diagnosis, distant metastasis to the lungs, bones, and bone marrow is detected, which significantly worsens the prognosis in 20–25 % of patients. The factors of an extremely unfavorable prognosis for the course of alveolar rhabdomyosarcoma are the occurrence of regional and distant metastases before the start of specific treatment, dissemination of the tumor lesion during treatment, and the presence of translocation of the 13q14 sector. Publications contain data on a high (11.2 %) prevalence of metastases of alveolar rhabdomyosarcoma in the pancreas. In the presence of metastatic lesions of the pancreas, surgical treatment is effective only in combination with chemoradiotherapy. Long-term results of treatment of this cohort of children are unsatisfactory due to the high risk of recurrence and dissemination of the tumor.Aim. To study risk factors, evaluate methods and prospects for the treatment of children with metastatic pancreatic lesions in parameningeal alveolar rhabdomyosarcoma. The article considers three clinical cases of such a lesion. We would like to draw the attention of pediatric oncologists and radiologists to the possible association of metastases in the pancreas in children with localization of rhabdomyosarcoma in the head and neck region, which requires improvement of examination protocols in this group of patients.
- 10 December 2022
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 12 (4) , 91-101
Open AccessDistant metastasis of alveolar rhabdomyosarcoma with pancreatic parameningeal localization in children: clinical case series
Rhabdomyosarcoma is a malignant neoplasm that develops from embryonic mesenchymal cells, with an annual incidence of 4.3 cases per 1,000,000 children. The prevalence of the tumor process is estimated on the basis of data from a comprehensive examination, including magnetic resonance imaging with intravenous contrast, ultrasound examination of the primary focus of regional and distant metastasis zones, computed tomography and radioisotope studies. The overall 5-year survival rate for localized rhabdomyosarcoma reaches 70 %. During the initial diagnosis, distant metastasis to the lungs, bones, and bone marrow is detected, which significantly worsens the prognosis in 20–25 % of patients. The factors of an extremely unfavorable prognosis for the course of alveolar rhabdomyosarcoma are the occurrence of regional and distant metastases before the start of specific treatment, dissemination of the tumor lesion during treatment, and the presence of translocation of the 13q14 sector. Publications contain data on a high (11.2 %) prevalence of metastases of alveolar rhabdomyosarcoma in the pancreas. In the presence of metastatic lesions of the pancreas, surgical treatment is effective only in combination with chemoradiotherapy. Long-term results of treatment of this cohort of children are unsatisfactory due to the high risk of recurrence and dissemination of the tumor.Aim. To study risk factors, evaluate methods and prospects for the treatment of children with metastatic pancreatic lesions in parameningeal alveolar rhabdomyosarcoma. The article considers three clinical cases of such a lesion. We would like to draw the attention of pediatric oncologists and radiologists to the possible association of metastases in the pancreas in children with localization of rhabdomyosarcoma in the head and neck region, which requires improvement of examination protocols in this group of patients.
- Open Access
- 16 August 2022
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 9 (2) , 93-105
Extraocular retinoblastoma: literature review and clinical case (intracranial retinoblastoma involving the visual tracts)
Relevance. Retinoblastoma (RB) is the most common primary intraocular tumor in children. The incidence of RB ranges from 1:14,000 to 1:20,000 newborns. To date, the survival rates of patients with RB reach almost 100 % with timely and adequate diagnosis. Among childhood oncological diseases, RB accounts for 2.3–4.5 % and 85–90 % among intraocular tumors in children. According to the volume of tumor spread, intra- and extraocular forms of the disease are distinguished. Extraocular RB is the spread of the tumor beyond the eye with invasion of the orbital tissues, as well as the possible involvement of adjacent areas, including intracranial without and with regional and/or remote metastases. The main method of treatment of children with extraocular RB is neoadjuvant chemotherapy (CT) with planning of surgical intervention and adjuvant therapy. High-dose CT (HDCT) with autologous hematopoietic stem cell transplantation (auto-HSCT), it allows to increase relapse-free survival in patients without metastatic lesions of the brain and spinal cord, but with their defeat, the prognosis of survival is extremely unfavorable, the nature of the disease is recurrent with 100 % lethality.Description of the clinical case. We report a case of bilateral RB: OD – with extraocular and intracranial spread of the tumor along the optic nerve with a lesion of the chiasm and a transition to the initial parts of the visual tracts. Secondary glaucoma. OS – with intraocular tumor growth in a 3-year-old child. After neoadjuvant chemotherapy, including intrathecal, a simultaneous two-stage operation was performed in the volume of bone-plastic (temporo-orbito-zygomatic) pterionic craniotomy on the right with prechiasmal resection of the right optic nerve and enucleation of the right eye. In the postoperative period, adjuvant chemotherapy was performed, followed by HDCT with auto-HSCT. Radiation therapy has become the final stage of treatment. Brachytherapy for OS tumor and remote radiotherapy for craniospinal region, right orbit, optic nerve stump with chiasm and pituitary pedicle were successively performed. After 14 months from the beginning of treatment and 5 months after its completion, a leptomeningeal relapse of the disease was detected.Conclusion. Rare observations of RB with damage to the visual tracts do not allow us to sufficiently study the features of the course of the tumor process, as well as to develop a single effective approach to antitumor treatment. Among the causes of mortality in patients with extraocular RB, the main one is metastasis, metastasis in the brain and spinal cord.
- 16 August 2022
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 9 (2) , 93-105
Open AccessExtraocular retinoblastoma: literature review and clinical case (intracranial retinoblastoma involving the visual tracts)
Relevance. Retinoblastoma (RB) is the most common primary intraocular tumor in children. The incidence of RB ranges from 1:14,000 to 1:20,000 newborns. To date, the survival rates of patients with RB reach almost 100 % with timely and adequate diagnosis. Among childhood oncological diseases, RB accounts for 2.3–4.5 % and 85–90 % among intraocular tumors in children. According to the volume of tumor spread, intra- and extraocular forms of the disease are distinguished. Extraocular RB is the spread of the tumor beyond the eye with invasion of the orbital tissues, as well as the possible involvement of adjacent areas, including intracranial without and with regional and/or remote metastases. The main method of treatment of children with extraocular RB is neoadjuvant chemotherapy (CT) with planning of surgical intervention and adjuvant therapy. High-dose CT (HDCT) with autologous hematopoietic stem cell transplantation (auto-HSCT), it allows to increase relapse-free survival in patients without metastatic lesions of the brain and spinal cord, but with their defeat, the prognosis of survival is extremely unfavorable, the nature of the disease is recurrent with 100 % lethality.Description of the clinical case. We report a case of bilateral RB: OD – with extraocular and intracranial spread of the tumor along the optic nerve with a lesion of the chiasm and a transition to the initial parts of the visual tracts. Secondary glaucoma. OS – with intraocular tumor growth in a 3-year-old child. After neoadjuvant chemotherapy, including intrathecal, a simultaneous two-stage operation was performed in the volume of bone-plastic (temporo-orbito-zygomatic) pterionic craniotomy on the right with prechiasmal resection of the right optic nerve and enucleation of the right eye. In the postoperative period, adjuvant chemotherapy was performed, followed by HDCT with auto-HSCT. Radiation therapy has become the final stage of treatment. Brachytherapy for OS tumor and remote radiotherapy for craniospinal region, right orbit, optic nerve stump with chiasm and pituitary pedicle were successively performed. After 14 months from the beginning of treatment and 5 months after its completion, a leptomeningeal relapse of the disease was detected.Conclusion. Rare observations of RB with damage to the visual tracts do not allow us to sufficiently study the features of the course of the tumor process, as well as to develop a single effective approach to antitumor treatment. Among the causes of mortality in patients with extraocular RB, the main one is metastasis, metastasis in the brain and spinal cord.
- Open Access
- 11 November 2021
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 11 (3) , 56-71
Evolution of treatment for children with esthesioneuroblastoma (1969–2019)
Introduction. Esthesioneuroblastoma is a rare neuroectodermal malignant tumor. The incidence of this tumor in children under 15 years of age is 0.1 per 100,000 pediatric population. The information on incidence, disease course, and treatment of esthesioneuroblastoma in children vary significantly and depend on the follow-up period and statistical methods.Objective – to assess risk factors for esthesioneuroblastoma and evaluate treatment strategies used in children and their prospects.Materials and methods. This study included 29 patients aged 2 to 17 years diagnosed with esthesioneuroblastoma and treated at the Research Institute of Oncology and Hematology, N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia between 1969 and 2019. The median age upon diagnosis was 10 years. Six patients (20 %) developed the disease early in their life (being under 3 years of age). Esthesioneuroblastoma was equally common in boys and girls. More than half of the patients (n = 15; 51 %) had stage IV disease. The primary tumor invaded the maxillary sinus (n = 25; 86 %), orbit (n = 10; 34 %), ethmoid sinus (n = 18; 62 %), and cranial cavity (n = 12; 41 %). The majority of children (n = 28; 96 %) received pharmacotherapy and radiotherapy (n = 27; 93 %); the total focal dose was 50 Gy in case of primary tumor. The affected cervical lymph nodes were irradiated in 10 (35 %) patients (total focal dose 40 Gy). Ten (35 %) patients have undergone surgery.Results. The follow-up period varied between 3 months and 50 years. Nine (34 %) patients are still alive. Fourteen patients (48 %) died due to tumor progression; 1 (3 %) patient died due to complications from special treatment. Five (17 %) patients were lost to follow-up at different stages.Conclusion. The following risk factors were associated with poor prognosis in children with esthesioneuroblastoma: disease onset in early childhood, no adequate diagnosis of distant metastases prior to specific treatment initiation, disseminated disease, and high Ki-67 index. In patients with advanced cancer, surgeries were effective only in combination with chemoradiotherapy. Long-term treatment outcomes in children with esthesioneuroblastoma are poor due to high risk of recurrence and tumor dissemination.
- 11 November 2021
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 11 (3) , 56-71
Open AccessEvolution of treatment for children with esthesioneuroblastoma (1969–2019)
Introduction. Esthesioneuroblastoma is a rare neuroectodermal malignant tumor. The incidence of this tumor in children under 15 years of age is 0.1 per 100,000 pediatric population. The information on incidence, disease course, and treatment of esthesioneuroblastoma in children vary significantly and depend on the follow-up period and statistical methods.Objective – to assess risk factors for esthesioneuroblastoma and evaluate treatment strategies used in children and their prospects.Materials and methods. This study included 29 patients aged 2 to 17 years diagnosed with esthesioneuroblastoma and treated at the Research Institute of Oncology and Hematology, N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia between 1969 and 2019. The median age upon diagnosis was 10 years. Six patients (20 %) developed the disease early in their life (being under 3 years of age). Esthesioneuroblastoma was equally common in boys and girls. More than half of the patients (n = 15; 51 %) had stage IV disease. The primary tumor invaded the maxillary sinus (n = 25; 86 %), orbit (n = 10; 34 %), ethmoid sinus (n = 18; 62 %), and cranial cavity (n = 12; 41 %). The majority of children (n = 28; 96 %) received pharmacotherapy and radiotherapy (n = 27; 93 %); the total focal dose was 50 Gy in case of primary tumor. The affected cervical lymph nodes were irradiated in 10 (35 %) patients (total focal dose 40 Gy). Ten (35 %) patients have undergone surgery.Results. The follow-up period varied between 3 months and 50 years. Nine (34 %) patients are still alive. Fourteen patients (48 %) died due to tumor progression; 1 (3 %) patient died due to complications from special treatment. Five (17 %) patients were lost to follow-up at different stages.Conclusion. The following risk factors were associated with poor prognosis in children with esthesioneuroblastoma: disease onset in early childhood, no adequate diagnosis of distant metastases prior to specific treatment initiation, disseminated disease, and high Ki-67 index. In patients with advanced cancer, surgeries were effective only in combination with chemoradiotherapy. Long-term treatment outcomes in children with esthesioneuroblastoma are poor due to high risk of recurrence and tumor dissemination.